AI drug discovery company

Healx

Data as of Oct 17, 2026.

Company facts

Founded

2014

ReportedSource for founded (opens in new tab)
Headquarters

United Kingdom (Cambridge)

ConfirmedSource for headquarters (opens in new tab)
Total funding

about $115M

ReportedSource for total funding (opens in new tab)

Latest funding round

Round: Series C
Date: Aug 1, 2024
Amount: $47M
Lead investor: R42 Group and Atomico (co-leads)

ConfirmedSource for the latest round (opens in new tab)

Drugs on the board

HLX-1502

Phase 2 registry

Neurofibromatosis type 1

Registry for HLX-1502 (opens in new tab)

Recent news

Aug 24, 2026

Dosed first patient in Phase 1/2 combination study

ReportedSource (opens in new tab)
Jul 22, 2026

Doses the first patient in a Phase 1/2 trial of HLX-4310 for relapsed or refractory osteosarcoma

ReportedSource (opens in new tab)
Feb 24, 2025

First patient dosed in INSPIRE-NF1 Phase 2 of HLX-1502

ConfirmedSource (opens in new tab)

Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.

Spot an error? Tell me and I'll fix it.